FDA Approval Alert: The Need-to-Know | Obecabtagene Autoleucel in B-Cell Acute Lymphoblastic Leukemia

In November 2024, the FDA approved obecabtagene autoleucel for patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

FDA Approves Obecabtagene Autoleucel in B-Cell ALL
FDA Approves Obecabtagene Autoleucel in B-Cell ALL
Article
Nov 8, 2024 9:14 PM
Results from the FELIX trial support the approval of obecabtagene autoleucel in B-cell ALL.